Back to News
Market Impact: 0.2
Onchilles Pharma Reports First Clinical Data at SITC 2026 That N17350 Could Turn One Tumor into a Personalized Cancer Vaccine
Source: Business Wire
Healthcare & BiotechTechnology & Innovation
Onchilles Pharma says it reported first clinical data on N17350 at SITC 2026, with the treatment potentially turning an individual tumor into a personalized cancer vaccine. The headline provides no clinical results, efficacy figures, or safety details, so the significance remains unclear.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Asian Markets Tally Losses From Worsening Global Rout
- AI’s Grip on Financial Markets Was Never Clearer on the Way Down
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- OpenAI valued at $1.25 trillion, as rival Anthropic nears its IPO
- AI Party isn't Ending Because Of The Blue Wave Says Ives